Lung Neoplasm
94
14
16
46
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.4%
6 terminated out of 94 trials
88.5%
+1.9% vs benchmark
7%
7 trials in Phase 3/4
20%
9 of 46 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 46 completed trials
Clinical Trials (94)
Patient Reported Outcomes Following Percutaneous Lung Ablation
Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
Lung Ultrasound to Assess Aeration Loss After Lung Resection Surgery
Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Functional Avoidance Radiation Therapy
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Mid-point Transverse Process to Pleura Block Versus Thoracic Paravertebral Block in Posterolateral Thoracotomy
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program in Patients With Cancer
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China
Facilitating Communication Study